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1211-Geneve 4, Switzerland
Nalidixic and five newer 4-quinolones, ciprofloxacin, enoxacin, norfloxarin,
ofloxacin and pcfloxacin were tested against S76 recent clinical aerobic bacterial
isolates. The 4-quinolones were regularly active (MIC90 < 4 mg/1) against the
following bacteria: Staphylococcus aweus, S. epidermidis, S. saprophyticus, different
Enterobacteriaceae, Haemophilus influenzae, Campylobacter jejuni, Pseudomonas
aeruginosa, Agrobacter spp., Aeromonas spp., Plesiomonas spp., Neisseria
meningitidis. Other bacteria were usually intermediately susceptible or resistant:
different streptococci, Luteria monocytogenes, Nocardia asteroides, P. maltophilia,
Achromobacter xylosoxydans and Akaligenes denitrificans. Ciprofloxacin was the
most potent compound, followed by ofloxacin and pefloxacin, norfloxacin and
enoxacin being less active. All the 4-quinolones were much more active than
nalidixic acid. The MBC/MIC ratios of the 4-quinolones were between 1 and 2 with
a majority of strains, and between 2 and 3 with Streptococcus agedactiae, Str.
faeccdis and L. monocytogenes. A two- to eight-fold increase of MIC was observed
by increasing the inoculum 10,000-fold with most of the strains tested. Susceptible
bacterial population of Klebsiella pneumoniae, Enterobacter cloacae, Serratia
marcescens and P. aeruginosa contained more clones resistant to nalidixic acid (104
to 10s at four times the MIC) than to 4-quinolones (105 to 10' at four times the
MIC). Supplementing the media with MgSO4 produced smaller inhibition zone
diameters with a disc diffusion method than those obtained with non-supplemented
agar, with all quinolone or strains. Less regular effect, or no effect was obtained
after supplementation with ZnSO4 or Ca(NO3)2.
Introduction
In contrast to nalidixic acid and early derivatives such as cinoxacin, rosoxacin or
flumequine, the activity of newer 4-quinolone compounds does not limit them to the
oral therapy of urinary tract infections caused by Enterobacteriaceae. Recently
developed 4-quinolone are characterized by a wider spectrum including Pseudomonas
spp., Legionella spp. (Greenwood & Laverick, 1983), Gram-positive bacteria and
obligate intracellular organisms such as Mycobacteriwn spp. (Gay, DeYoung &
Roberts, 1984) or Chlamydia spp. (Heesen & Muytiens, 1984; von Roosbroeck,
Privinciael & Caekenberghe, 1984) and Mycoplasma spp. (Ridgway et al., 1984). In
contrast, the activity against anaerobic bacteria is limited. The extremely low MICs of
4-quinolones against aerobic bacteria and their pharmacokinetic properties suggests
their use in numerous clinical situations. In the present study we compare the in-vitro
activity of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against
routine clinical isolates of aerobic Gram-positive and Gram-negative organisms.
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Material and methods
Antimicrobial agents. Standard powder of the following drugs were obtained from
their manufacturers: Nalidixic acid (Winthrop, Switzerland), ciprofloxacin (Bayer AG,
Germany), enoxacin (Roger Bellon, France), norfloxacin (Merck Sharp and Dohme,
Switzerland), ofloxacin (Roussel-Hoechst, France) and pefloxacin (Rhone Poulenc,
France). Antibiotic solutions were prepared in water or in broth and used immediately.
Bacterial strains. Five hundred and seventy-six clinical strains collected from patients
hospitalized in the University Hospital of Geneva or, occasionally, in other Swiss
hospitals, and seven ATCC control organisms were used. They were kept frozen in
skim milk at — 70°C. Before study, organisms were thawed, streaked onto sheep blood
agar and incubated overnight at 35°C.
Antimicrobial susceptibility tests. Antimicrobial activity was measured by the
microdilution method in Mueller-Hinton broth (NCCLS, 1983). Disposable material
was used exclusively in order to avoid cross-contamination with quinolones. The final
inoculum of 103-106 cfu/ml was prepared from a trypticase soy broth inoculated 4 h
before and controlled by counting the bacteria in a calibrated volume. The inoculum
for Haemophilus influenzae was prepared and tested in Brain Heart Infusion broth
supplemented with 5% nicotinamide diphosphate and 10% haemin. The minimal
inhibitory concentration (MIC) was read after 18 h of incubation at 35°C in air or at
42°C in 10% CO2 atmosphere for Campylobacter jejuni. The minimal bactericidal
concentration (MBC) was determined by subculturing 001 ml on Mueller-Hinton
agar and defined as 99-9% reduction in the initial inoculum. Nocardia asteroides was
tested by agar dilution on Mueller-Hinton agar with 10* cfu/spot with 35°C
incubation for three days.
Effect of calcium and magnesium. Defined medium (Iso-sensitest agar, Oxoid)
containing 0-3 mmol Ca2 + , 1-2 mmol Mg2+ and 0014 mmol Zn2+ respectively was
supplemented in order to obtain a final concentration of 0-8 or 2-8 mmol/1 Ca(NO3)2,
2-8 or 50 mmol/1 MgSO4, and 003 or 007 mmol/1 ZnSO*.
Inoculum effect. This effect was measured on Mueller-Hinton agar with 108 or
10* cfu per inoculum.
Results
MICs of quinolones
Against Gram-positive genera, nalidixic acid had very poor activity as shown in Table
I. In contrast 96 out of 97 staphylococci were susceptible to 4-quinolones; the
exception was one methicillin resistant Staphylococcus aureus which was resistant to
the quinolones tested. Activity of quinolones was similar against S. epidermidis and
three groups of S. aureus classified according to their susceptibility to penicillin G and
methicillin. S. saprophyticus was found to be one- or two-fold less susceptible than
S. epidermidis. Streptococci were far less susceptible than staphylococci, most of the
strains being in the intermediate susceptibility range. MICs of quinolones were similar
against Streptococcus pneumoniae, Str. agalactiae and Str. faecalis. The majority of
Listeria monocytogenes and N. asteroides were resistant to all quinolones tested except
for a few sensitive strains. Quinolones were more active against the Enterobacteriaceae
(Table II) than against Gram-positive bacteria. Most strains being inhibited by
Table
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I. Activity of quinolones against Gram positive bacteria
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Organisms
(number)
Penicillin-sensitive
S. aweus (20)
Penicillin-resistant
Oxacillin-sensitive
S. aweus (19)
Oxacillin-rcsistant
S. aweus (24)
S. epidermidis (22)
S. saprophyticus (12)
Str. pneumoniae (31)
Str. agalactiae (19)
Str.faecalis (22)
Antibiotic
nalidixic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
MIC30
(mg/1)
64
0-25
1
1
0-25
0-5
64
0-25
1
2
0-25
0-5
64
0-25
1
1
0-25
0-5
64
0-125
1
0-5
0-125
0-5
>128
0-25
2
2
0-5
2
128
0-5
8
4
0-5
4
>128
0-5
32
4
1
8
>128
0-5
8
4
1
4
MIC90
(mg/1)
>128
0-5
4
2
1
1
128
0-5
2
2
0-5
0-5
128
0-5
2
2
0-5
1
128
0-25
1
2
0-25
1
>128
0-5
4
4
1
4
>128
1
16
8
1
8
>128
0-5
32
16
1
16
>128
0-5
8
4
2
4
Range
(mg/1)
32->128
0-125-0-5
0-5^1
0-5-2
0-125-1
0-25-4
32-128
0-125-1
0-5^*
0-5-4
0-125-0-5
0-25-1
32->128
0-125-4
0-5-32
O-5->32
0125-2
0-25-8
64->128
0125-0-25
0-5-2
0-5-2
0-125-1
0-5-2
128->128
0-125-0-5
1^*
0-5-4
0-25-1
1^ »
32-> 128
006-1
4-16
2-32
0-015-1
4-8
>128
0-25-1
8-32
4-16
0-25-2
4-32
>128
0-25-0-5
4-8
1-A
1-2
2-4
32
Table I—contd.
Organisms
(number)
L. monocytogenes (26)
N. asteroides (19)
R. Acickenthaler et aL
Antibiotic
nalidixic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pcfloxacin
nalidixic acid
ciprofloxacin
norfloxacin
ofloxacin
pefloxacin
MIC30
(mg/1)
>128
0-5
8
4
1
8
>128
4
32
4
32
MIC90(mg/1)
>128
1
16
8
2
8
> 128
8
64
16
64
Range
(mg/1)
>128
0-25-1
4-16
2-16
0-5-2
2-8
64->128
0-25-32
2-64
0-5-64
2-64
Table IL Activity of quinolones against Entcrobacteriaceae
Organisms
(number)
E. coli (30)
Salmonella spp. (22)
Shigella spp. (26)
Y. enterocolitica (7)
Antibiotic
nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
MIC30
(mg/1)
4
2
0015
0125
0-06
006
0-5
4
2
0008
0-25
006
0-03
0125
2
0-25
0008
0125
0-06
006
0-125
2
0-25
0-015
125
0125
0-06
0125
MIC90
(mg/1)
4
2
003
1
0-5
006
0125
8
4
0015
0-25
0125
006
0-25
4
0-25
0-03
0125
0-06
0125
0125
4
2
0-03
0-25
0125
0-125
0-25
Range
(mg/1)
2-> 128
0-25->128
0-004-1
0-125-8
0-06-4
0-015-2
0-06-8
2-8
0-25-4
0004-0015
0125-0.25
006-0125
0015-0-25
0-06-0.25
2-4
0-125-0-25
0-004-0-06
0-06-0-25
0-06-0.125
0-03-1
0-06-0-125
l^t
0-25-4
0008-0.03
0125-0-25
006-0-125
0-03-0-125
0-125-0-25
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Table U—contd.
Organisms Antibiotic
(number)
Klebsiella spp. (29) nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
Enterobacter spp. (27) nalidixic acid
pipemidic acid
ciprofloxacin
cnoxacin
norfloxacin
ofloxacin
pefloxacin
Ser. mwcescens (23) nalidixic acid
pipemidic acid
ciprofloxacin
cnoxacin
norfloxacin
ofloxacin
pefloxacin
Citrobacter freundii (13) nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
Proteus spp. (30) nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
Morganella morganii (16) nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
Providencia rettgeri (6) nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
MIC30(mg/1)
4
0-5
0-015
0-25
0-125
0-125
0-25
8
2
0015
0-25
0125
0125
0-25
4
0-5
0-125
0-5
0-25
0-5
0-5
8
0-5
0-008
0-25
0-25
0-06
0-125
8
0-5
0015
0-5
0-125
0125
0-25
4
0-25
0-015
0-25
0-06
0125
0-25
4
0-5
0-03
0-25
0125
0-25
0-25
MIQ.0
(mg/1)
8
4
0-06
0-5
1
0-25
0-5
32
4
003
0-5
0-5
0-5
1
16
16
1
2
1
> 2
1
32
0-5
0-015
0-5
1
0-25
1
16
4
0-03
0-5
0-25
0-25
0-25
8
0-5
0-03
0-5
0125
0-25
0-5
8
0-5
0-25
0-5
0-125
1
0-25
Range
(mg/1)
1-16
0-25-16
0-008-0-25
0-06-1
0-03-8
0-015-0-5
0-03-1
4-32
0-25-16
0-004-0-06
0-125-1
0-06-1
0-03-0-5
0125-1
2-32
0-25-32
O-015->2
0-125-4
0-125-2
0125->2
0-125-4
4-64
0-25-1
0004-0-5
0125-2
0125-1
0-03-1
0-06-2
2-32
0-25-4
0-008-0-25
0-125-1
0-03-0-5
0-03-0-25
0125-0-5
2-16
0-25-2
0-004-0-03
0125-0-5
0-03-0-125
0-06-0-25
006-0-5
2-> 128
0-5-32
0-008-2
0125-16
006-16
0015->2
0-125-16
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Table IIL Activity of quinolones against other aerobic and microaerophilic Gram-negative
bacteria
Organisms
(number)
H. influenzae (18)
C. jejuni (24)
P. aeruginosa (19)
P. maltophilia (7)
Other Pseudomonas spp.
(not aeruginosa) (8)
Achromo. xylosoxydans
and Alcalig.
denitrificans (6)
Acinetobacter spp. (15)
Antibiotic
nalidixic acid
pipemidic acid
ciprofloxacin
cnoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
pipemidic acid
ciprofloxacin
cnoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
MIC50
(mg/1)
1
2
0-008
0-125
0-06
0-015
0-03
8
16
0-25
1
1
0-5
0-5
128
32
0-125
1
1
2
2
8
>64
4
8
16
> 2
2
4
4
0125
0-5
0-5
0-25
1
16
128
2
16
>32
4
8
4
16
006
0-5
2
0-25
0-25
MIC,0
(mg/1)
1
4
0-008
0125
0-06
0-03
0-03
16
64
1
8
8
2
2
128
64
0-25
2
2
2
4
16
>64
4
8
32
> 2
4
64
8
2
2
2
1
2
32
>128
> 2
>32
>32
32
16
8
128
006
4
16
1
1
Range
(mg/1)
0-5-2
2-128
0004-0015
0-06-0-5
0-03-1
0-015-0-5
<0015-l
4-128
8-128
0-25-2
0-5-8
0-5-8
0-25-2
0-25^t
64-128
16-64
0-06-0-25
0-5-2
0-5-2
0-O6->2
1-4
8-16
>64
2-8
4-16
16->32
> 2
2-4
0-5-64
2-64
003-2
0-06-4
0 0 6 ^
0-06-2
0<kM
16-32
>128
l - > 2
16->32
>32
4-32
4-16
0-5-8
1-128
0-004-0125
0-004-4
0-03-32
0015-1
0-03-4
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Table VH—contd.
Organisms
(number)
Agrobacter spp. (20)
Aeromonas and
Plesiomonas spp. (19)
N. meningitidis (18)
Antibiotic
naJidixic acid
pipemidic acid
ciprofloxacin
cnoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
pipemidic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
nalidixic acid
ciprofloxacin
enoxacin
norfloxacin
ofloxacin
pefloxacin
MIC5 0
(mg/1)
16
4
0-06
0-25
0-5
0-25
0-25
1
0-125
0-004
0-06
0-03
0-015
<0-015
1
0-002
0-03
0-03
0-008
0-03
MIC9 0
(mg/1)
16
4
0-06
0-5
1
0-5
0-25
2
0-25
0-008
0125
0-06
0-015
0-06
2
0-004
0-06
0-03
0-015
0-03
Range
(mg/1)
8-32
2-32
0-03-0-06
0-25-0-5
0-125-1
0-25-1
0-125-O-5
0-5-2
0-125-0-5
<O001-0O15
0-03-0-125
<<M)15-O-O6
0-008-0-03
<0-015-O-O6
0-5-2
0O02-O-004
<O015-0-06
< 0-015-0-03
0-004-0-015
<(H)15-0-06
< 1 mg/1. Some genera were rather more susceptible, such as Escherichia coli,
Salmonella spp., Shigella spp. and Yersinia enterocolitica, while others were distinctly
more resistant, such as Enterobacter spp., Serratia marcescens and Providencia rettgeri.
Although not shown in Table II, ampicillin, carbenicillin, cephalothin, cefotaxime,
gentamicin and amikacin were tested simultaneously with the quinolones. Many of the
strains of enterobacteria used were resistant to penicillins, cephalothin and gentamicin.
No relationship between resistance to these agents and to 4-quinolones could be found.
However, several strains showed a high level of resistance to nalidixic acid not seen
with the 4-quinolones. As well as the Enterobacteriaceae, many other aerobic Gram-
negative bacteria were susceptible to quinolones (Table III). These agents were
extremely active against Aeromonas spp., Plesiomonas spp., Neisseria meningitidis and
H. influenzae. Among the pseudomonas, P. maltophilia was more resistant than
P. aeruginosa. The quinolones showed activity against C. jejuni and Agrobacter spp.
comparable to that against the majority of enterobacteria, while Achromoxylosoxydans
and Alcaligenes denitrificans were generally resistant. Acinetobacter spp. were
susceptible to wide range concentrations of quinolones.
Comparing the activity of the different quinolones tested on a weight basis,
ciprofloxacin was the most potent compound, followed by ofloxacin and pefloxacin.
Norfloxacin and enoxacin were less active than pefloxacin. Differences between these
compounds were more pronounced with Gram-negative bacteria than with Gram-
positive genera. All the 4-quinolones were more active than nalidixic acid.
MBCs of quinolones. The MBC/MIC ratios of pefloxacin, norfloxacin and enoxacin
were between 1 and 2 for the majority of strains, and between 2 and 3 with Str.
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Table IV. Mean MDC/MIC ratios for five quinolones
Organisms
Number Nalidixic Cipro- Nor-
tested acid floxacin Enoxacin fioxacin Pcfloxacin
PeniciUin-sensitive 14 1-7 1-5 1-64 1-64 1-4
S. aureus
Penicillin-resistant 11 2-3 2-4 1-45 2-0 1-9
Methicillin-sensitive
S. aureus
Penicillin-resistant 16 1-7 2-7 1-6 2-2 1-7
Methicillin-resistant
S. aureus
S. epidermidis 17 1-7 2-9 1-7 1-9 1-4
S. saprophyticus 11 inactive 2 1 1-6 1-7 1-2
Str. agalactiae 14 inactive 2-0 N.D. 2-6 2-5
Str. faecalis 16 inactive 1-6 3-5 21 2-9
Str. pneumonias 11 inactive 1-3 1-3 1-3 1-2
L. monocytogenes 10 inactive 21 2-4 2-2 1-9
E. coli 12 21 10 1-3 1-6 1-8
Shigella spp. 24 1-8 N.D. 11 1-3 11
Salmonella spp. 29 2-2 10 1-6 1-2 1-5
Enterobacter spp. 13 1-5 1-0 1-3 11 11
Klebsiella spp. 15 30 11 1-3 1-3 1-7
Serratia spp. 18 3-2 N.D. 1-8 21 21
Proteus spp. 20 20 1-4 1-6 1-5 1-8
P. aeruginosa 10 1-7 4-5 1-6 1-8 1-9
Pseudomonas spp. 15 2-7 2-5 1-8 21 1-9
(not aeruginosa)
* N.D. = not determined.
agalactiae, Str. faecalis and L. monocytogenes (Table IV). In comparison with these
three agents, bactericidal activity of ciprofloxacin was somewhat different, with higher
MBC/MIC ratios against most staphylococci and Pseudomonas, but lower ratios
against Str. agalactiae, Str. faecalis, and enterobacteria.
Inoculum effect and mutational frequencies. Determinations of MICs with two
inocula of 104 and 108 cfu showed an inoculum effect particularly obvious with
Enterobacter cloacae and Ser. marcescens (Table V). The inoculum effect was most
Table V. Fold increase of MICs with an inoculum of 108 cfu per spot as compared to an
inoculum of 104 cfu per spot
Strains
Fold increase of MICs range with:
Number nalidixic cipro- nor-
tested acid floxacin enoxacin floxacin pefloxacin
E.coli
K. pneumoniae
E. cloacae
Ser. marcescens
P. aeruginosa
S. aureus
Str. faecalis
4
4
4
4
4
4
4
1^*
4-8
8-32
8-16
4-16
2-4
resistant
2-4
2-8
1-16
4-16
4-8
2-4
2-8
1-2
1-4
1-32
8-32
2-8
1-4
8-16
1-2
2-8
2-8
8
4-16 ,
2-4
1-4
2
2-8
4-16
4-8
2-8
2-4
2-8
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Table VI. Log values of the number of colonies growing on Mueller-Hinton Agar containing
quinolone concentrations four or eight times the MICs (inoculum: 109 cfu)*
Strains
(number)
E. coli (4)
K. pneumoniae (4)
E. cloacae (4)
Ser. marcescens (4)
P. aeruginosa (4)
S. aureus (4)
Log of colonies growing at four or eight times the
nalidixic
acid
4x
MIC
0
1-2
1-2
2-4
1-2
3-5
8x
MIC
0
0
1-2
1-3
0-2
0
cipro-
floxacin
4x
MIC
0
0-1
0-2
0-4
1-3
0-2
8x
MIC
0
0
0-2
0-2
0
0
enoxacin
4x
MIC
0
0-2
0-2
2-4
1-2
0
8x
MIC
0
0
0-2
0-4
0-1
0
nor-
floxacin
4x
MIC
0
0-2
0-2
2-4
1-2
0-1
8x
MIC
0
0-1
0-1
0-1
0-2
0-1
MIC of:
ofloxatin
4x
MIC
0
0-2
0-3
0-4
0-2
0
8x
MIC
0
0-1
0-2
0-2
0-1
0
pefloxacin
4x
MIC
0
0-2
0-2
1-3
0-2
0-2
8x
MIC
0
0
0-2
0-1
0-1
0-1
• No colonies grew at 16 times the MIC with either compound.
marked with nalidixic acid while the differences found between the 4-quinolones were
not significant. Data of Table V correlated well with determination of mutation
frequencies shown in Table VI. E. coli populations contained less than 109 mutants
resistant to the quinolones tested. Within the other strains studied, Ser. marcescens and
E. cloacae had the highest frequency of mutants, and we found more clones resistant to
nalidixic acid (10*—108 at a concentration of four times the MICs) than to 4-quinolones
(105-109 at four times the MICs). All the 4-quinolones tested selected resistant mutants
at similar frequencies. No colonies grew at 16 times the MICs with either compounds.
Influence of cation supplementation. Addition of 003 or 006 mmol of ZnSO4 did not
alter the size of the inhibition zone diameters produced by ciprofloxacin, ofloxacin,
pefloxacin and gentamicin when testing six strains in a disc-diffusion method
(Figure 1). Supplementation with Ca(NO3)2 reduced the inhibition zone diameters of
ofloxacin, pefloxacin and gentamicin but not those of ciprofloxacin. Supplementation
with MgSO4 produced significantly smaller inhibition zone diameters than those
obtained with non-supplemented agar in all cases, whatever the antibiotic or the strain
considered.
Control
CotNOjlj O-8
Co(NOj)2 2-8
MqSQ, 28
MgS04 5O
ZnS04 0O3
ZnS04 0O7
Control
Co(NOj)2 O-8
Co(NOj)2 2-8
MqSOt 28
MqS04 5O
ZnS04 OO3
ZnS04 0O7
Gprofknocin
-»—I
I—i
-I—I
Refkwocm
Oflouxin
Gentomicin
i h
i 1
I I
20 30 40 20
Zone sue (mm)
30 40
Figure 1. Influence of cation supplementation on the inhibition zone size obtained by disc diffusion with
four antibiotics.
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Discussion
Newer 4-quinolones are characterized by a broader spectrum of activity when
compared to nalidixic acid. The data of this study confirm the similarity of the
antibacterial spectrum for the 4-quinolone compounds tested (Wise, Andrews &
Edwards, 1983; Barry et al, 1984; Bauerafeind & Petermuller, 1984; van
Caekenberghe & Pattyn, 1984; Chin & Neu, 1984; Hoogkamp, 1984). 4-quinolones are
active against all Enterobacteriaceae, including Enterobacter spp. or Ser. marcescens
which are often resistant also to newer cephalosporins. In particular organisms causing
diarrhoea including Campylobacter spp. are very sensitive and may therefore be useful
in this clinical situation. Against P. aeruginosa the activity is modest and not related to
concomittant resistance to carbenicillin or gentamicin. Other non-fermenters such as
P. maltophilia, Achromobacter spp. or Alcaligenes spp. are more than ten times less
sensitive and often resistant to quinolones. The spectrum of 4-quinolones also includes
Gram-positive organisms including staphylococci and to a lesser degree streptococci
and Listeria spp. The MICs of Nocardia spp. are close to the achievable peak serum
levels of quinolones and therefore cannot be recommended for clinical trials. As found
by other authors (Bauernfeind & Petermuller, 1984; van Caekenberghe & Pattyn,
1984) the activity on a weight basis is highest for ciprofloxacin, followed by pefloxacin
and ofloxacin, norfloxacin, enoxacin and the least active nalidixic acid. However, this
observation will have to be matched with pharmacokinetics and clinical results,
because other examples have taught, that in-vitro activity is not a sufficient criterion for
the evaluation of new antimicrobial agents.
The bactericidal activity of quinolones is in general within 1-2-fold the MIC. Only
Str. agalactiae, Str. faecalis, and L. monocytogenes have MBC two to three times
higher than the MIC. Therefore the use of quinolones particularly for enterococcal
endocarditis has first to be confirmed in the animal model. Ciprofloxacin has higher
MBC-MIC ratios against P. aeruginosa when compared to the other 4-quinolones.
Emergence of resistance during therapy has been noted with nalidixic acid (Slack,
1984), and newer 4-quinolones (Acar, Kitzis & Goldstein, 1985; Lauwers et al., 1985).
In this study we have evaluated the frequency of resistant mutations by measuring the
increase of MIC by raising the inoculum 10,000 fold. The increase was two- to eight-
fold for most of the organisms tested. However, Enterobacter spp. and Ser. marcescens
both well known for emergence of resistance during therapy with cephalosporin
(Sanders & Sanders, 1985), again have a higher increase of the MIC up to 32 times and
this could well explain the clinical failures. The mechanism of resistance is not known,
but could be explained by a defect in bacterial penetration as the observation is
common to all 4-quinolones tested (Smith, 1984).
The influence of pH, cations and various media has been mentioned by various
authors. We have measured the influence of increased calcium, magnesium or zinc
concentration on the zone size of a disc diffusion test. At the tested concentrations only
magnesium reduced the zone size significantly for all compounds. The mechanism of
impaired activity in presence of magnesium is unknown. Possibly, magnesium might
interfere at least at two levels, either on the outer membrane as is the case with
aminoglycosides, or at the level of DNA-gyrase-DNA interaction. The clinical
significance of the magnesium effect is unknown. However, increased magnesium
concentrations in the urine, together with a low pH, could be responsible for impaired
therapeutic response in difficult to treat urinary tract infections. In addition, in testing
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susceptibility of 4-quinolones, concentration of the magnesium in the medium should
be standardized.
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